Perinatal Depression: A Guide to Detection and Management in Primary Care

Manish H. Dama, MPH, and Ryan J. Van Lieshout, MD, PhD, FRCP (C)

Introduction: Existing guidelines for primary care clinicians (PCCs) on the detection and management of perinatal depression (PD) contain important gaps. This review aims to provide PCCs with a summary of clinically relevant evidence in the field.

Methods: A narrative literature review was conducted by searching PubMed and PsycINFO for articles published between 2010 to 2023. Guidelines, systematic reviews, clinical trials, and/or observational studies were all examined.

Results: Screening with the Edinburgh Postnatal Depression Scale or Patient Health Questionnaire-9 followed by a diagnostic evaluation for major depressive disorder in probable cases can enhance PD detection. At-risk individuals and mild to moderate PD should be referred for cognitive behavioral therapy or interpersonal psychotherapy when available. Selective serotonin reuptake inhibitors should be used for moderate to severe PD, with sertraline, escitalopram, or citalopram being preferred first. Using paroxetine or clomipramine in pregnancy, and fluoxetine or doxepin during lactation is generally not preferred. Gestational antidepressant use is associated with a small increase in risk of reduced gestational age at birth, low birth weight, and lower APGAR scores, though whether these links are causal is unclear. Sertraline and paroxetine have the lowest rate of adverse events during lactation.

Consequences of untreated PD can include maternal and offspring mortality, perinatal complications, poor maternal-infant attachment, child morbidity and maltreatment, less breastfeeding, and offspring developmental problems.

Conclusions: These clinically relevant data can support the delivery of high-quality care by PCCs. Risks and benefits of PD treatments and the consequences of untreated PD should be discussed with patients to support informed decision making. (J Am Board Fam Med 2023;36:1071–1086.)

Keywords: Breast Feeding, Interpersonal Psychotherapy, Lactation, Postpartum, Psychosocial Intervention, Postpartum Depression, Pregnancy, Psychiatry, Selective Serotonin Reuptake Inhibitors, Surveys and Questionnaires

Introduction

Major depressive disorder (MDD) occurring during pregnancy and/or the first postpartum year (ie, perinatal depression [PD]) is a significant public health problem. With a prevalence of 9.2 to 17.0%, PD is associated with an increased risk of maternal and offspring morbidity and mortality, as well as perinatal complications, impaired maternal-infant attachment, and poorer breastfeeding practices. It also raises depression risk in partners and a single untreated PD case can cost society $USD 97,209 (£73,728 [June 16th, 2023]) over the lifespan.

Unfortunately, up to 69% of PD cases go undetected, and just 6% of those identified receive evidence-based treatment. Research suggests that primary care clinicians (PCCs) receive limited training in perinatal mental disorders, including evidence-based methods of detection. Two recent reviews suggest that existing guidelines for PCCs (eg, 2016 United States Preventive
Service Task Force [USPSTF] recommendation statement34 may be less clear than is ideal in describing which pharmacologic agents should be prescribed perinatally. Furthermore, PCCs generally feel that existing guidelines provide minimal information on the safety of antidepressants perinatally, which leads them to have to consult with other sources (eg, pharmacists and psychiatrists) before prescribing them to those with PD.30,31 These issues may contribute to the low uptake of guideline recommendations for PD among PCCs,30–32 despite the fact that they feel more responsible for detecting and managing PD than obstetricians or pediatricians.30

To support PCCs in providing better care to individuals with PD, we conducted a narrative literature review in which the primary aim was to summarize existing evidence for detecting and managing PD with a focus on clinical relevance. A secondary aim was to provide up-to-date data on the risks of perinatal antidepressant use and the consequences of untreated PD to help guide PCCs in their ability to support informed decision making for patients.

Methods
PubMed and PsycINFO were searched for published articles between January first, 2010 to June sixth, 2023 using the following key terms: perinatal depression, postpartum depression, antenatal depression, guideline, diagnosis, psychosocial intervention, psychotropic drugs, teratogens, breastfeeding, and lactation. Guidelines, systematic reviews, controlled studies, or observational research addressing the aims of our review were included. Reference sections of included articles were also examined for any pertinent citations relevant to our review.

We first considered the work of specialist guidelines followed by systematic reviews of randomized controlled trials (RCTs) and then individuals RCTs. If unavailable, we then considered systematic reviews of observational research followed by large individual observational studies. Search for articles were performed between September 1, 2022, and June 6, 2023.

The Strength of Recommendation Taxonomy35 was used to evaluate evidence for detecting and managing PD. When possible, we described the magnitude of applicable risks (eg, risk ratio) reported among included studies to enhance their clinical relevance. A relative risk of 2 or more (Risk ≥2.0) is generally accepted as being clinically significant at the level of an individual patient.36 To ensure that our narrative literature review was conducted and reported appropriately, we followed recommendations from the Scale for the Assessment of Narrative Review Articles (SANRA),37 a quality assessment tool for narrative reviews.

Detection of Perinatal Depression
The USPSTF recommends that all perinatal individuals be screened for depression with the Edinburgh Postnatal Depression Scale38 (EPDS) followed by a diagnostic evaluation for MDD among those identified as probable cases.34 Screening programs for PD have been proven to be efficacious in reducing PD onset39 (Table 1). The EPDS is a free, 10-item self-report questionnaire that focuses on the affective and cognitive symptoms of MDD.38 It has been translated into 50 languages and only takes 5 minutes to complete.40 Although the USPSTF did not recommend a specific cutoff score,34 an EPDS score of ≥10 may suggest PD.41 However, more recent data suggest that an EPDS score of ≥11 may provide the best combination of sensitivity and specificity.42 The following EPDS ranges can be considered when assessing PD severity: none-to-minimal depression (0 to 6); mild depression (7 to 13); moderate depression (14 to 19); and severe depression (19 to 30).43 Given that PD cases commonly present with elevated levels of anxiety,44,45 EPDS items 3 to 5 (EPDS-3A Scale) can help monitor anxiety symptoms among PD cases46 and screen for a possible comorbid anxiety disorder with an EPDS-3A cutoff score of ≥5.47,48

The National Institute for Health and Care Excellence (NICE; UK perinatal psychiatric guidelines) and the American Academy of Pediatrics (AAP) recommend the use of the Patient Health Questionnaire-999 (PHQ-9) for assessing individuals who may have PD.41,50 A PHQ-9 score ≥10 seems to have a good level of sensitivity and specificity for detecting probable PD cases.51 Within USA settings, the PHQ-9 may be more practical to use than EPDS given that its generally used in primary care to screen for depression among the general population34 and could prevent PCCs from having to learn and use another depression screening tool. In addition, USA primary care sites are measured by their use of PHQ-9 for quality and

1072 JABFM November–December 2023 Vol. 36 No. 6 http://www.jabfm.org
<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Evidence Rating</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>Recommendations for screening of perinatal depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screen all perinatal individuals with EPDS or PHQ-9 to identify probable cases</td>
<td>USPSTF guidelines gave a grade of “B” for the recommendation of screening all perinatal individuals for depression in primary care. 6 controlled studies (5 RCTs and 1 controlled trial) included in this systematic review demonstrates that screening programs were more effective than controlled interventions in reducing the absolute risk of developing depression later on in the perinatal period (Absolute Risk Reduction: 2.1% to 9.1%), but majority of these trials had low-quality study designs. NICE and AAP guidelines suggest that the PHQ-9 is a suitable instrument to investigate for perinatal depression.</td>
<td></td>
</tr>
<tr>
<td>of probable cases of perinatal depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use an EPDS cut-off score ≥ 11 to screen for probable cases of major depressive</td>
<td></td>
<td>A recent meta-analysis of individual participant data (n = 58 studies; 15,557 participants) suggest that an EPDS cut-off score of ≥ 11 has the best combination of sensitivity (0.81–0.90) and specificity (0.83–0.88) for identifying perinatal major depression in reference to either a semi- or fully-structured diagnostic interview.</td>
</tr>
<tr>
<td>disorder during the perinatal period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A cut-off score ≥ 10 on the PHQ-9 can also be used to screen for probable cases</td>
<td></td>
<td>One meta-analysis (n = 7 studies) suggests that a PHQ-9 cut-off score of ≥ 10 has a good level of sensitivity (0.84, 95% CI: 0.75–0.90) and specificity (0.81, 95% CI: 0.74–0.86) for identifying perinatal major depression in reference to a diagnostic interview.</td>
</tr>
<tr>
<td>of major depressive disorder during the perinatal period</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screen for antenatal depression in the first trimester and again in the third</td>
<td>A consensus-based recommendation made by COPE guidelines; COPE recommends to screen for depression at the first antenatal visit (first trimester) and again either at or around 30 weeks gestation (third trimester).</td>
<td></td>
</tr>
<tr>
<td>trimester</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Screen for postpartum depression at 1-, 2-, 4-, and 6-months postnatally</td>
<td>Screening for PPD at 1-, 2-, 4-, and 6-months postnatally is a consensus-based recommendation made by the AAP guidelines.</td>
<td></td>
</tr>
<tr>
<td>Consider screening for postpartum depression up to 12-months postnatally to help</td>
<td>Screening for PPD up to 12-months postnatally is suggested based on the CDC identifying that a large proportion of maternal deaths postnatally occur between 6 to 12 months postpartum and mental health conditions are the leading cause of postnatal maternal mortality.</td>
<td></td>
</tr>
<tr>
<td>reduce postnatal maternal mortality</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recommendations for managing perinatal depression</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Therapist-delivered online or in-person CBT or IPT in individual or group format</td>
<td>Guidelines including USPSTF, CANMAT, COPE, and NICE supports therapist-delivered CBT and IPT as first-line interventions for PD of mild to moderate severity. One recent meta-analysis of RCTs indicated that psychotherapies are efficacious in reducing perinatal depressive symptoms (Hedge’s g = 0.67, 95% CI: 0.45–0.89; NNT: 4.4) and the results from most of the RCTs are consistent with the direction of the overall effect measure (25/43 RCTs), but a large proportion of these trials had low-quality study designs.</td>
<td></td>
</tr>
<tr>
<td>should be considered as a first-line intervention for perinatal depression of</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mild to moderate severity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Social/peer-support, mindfulness-based interventions, and structured exercise</td>
<td>Despite each of these interventions described below receiving a SORT evidence rating of “B”, there is substantially more evidence examining therapist-delivered CBT/IPT and antidepressant monotherapy in the management of major depressive disorder. Therefore, these interventions should only be considered as adjuncts to therapist-delivered CBT/IPT or antidepressant monotherapy in the management of perinatal depression of mild to moderate severity.</td>
<td></td>
</tr>
<tr>
<td>programs with moderate intensity (≥150 minutes/week) can each be considered as a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>possible adjunct to therapist-delivered CBT/IPT or antidepressant monotherapy in</td>
<td></td>
<td></td>
</tr>
<tr>
<td>the management of perinatal depression of mild to moderate severity</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Continued
reimbursement, and so may prefer to use PHQ-9 to screen for PD. Lastly, there is more supportive training and material for PHQ-9 than EPDS within USA settings. PCCs should be aware that PHQ-9 measures somatic symptoms of MDD, which can be influenced by the physiologic changes occurring in the perinatal period.40,52

PCCs should consider following the Centre of Perinatal Excellence (COPE; Australian perinatal psychiatric guidelines) recommendation of screening for pregnancy-related MDD (antenatal depression [AD]) at least during the first and third trimesters,53 which is when AD prevalence is highest.2 For postpartum MDD (PPD), PCCs can consider following

Table 1. Continued

<table>
<thead>
<tr>
<th>Recommendations</th>
<th>Evidence Rating</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Social/peer support:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supported by COPE guidelines to use as an intervention for perinatal individuals with depressive symptoms;51</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Although this meta-analysis of RCTs found that social/peer-support programs are efficacious in reducing perinatal depressive symptoms (SMD: −0.37, 95% CI: −0.66 to −0.08), the individual results from most of these RCTs are inconsistent with the direction of the overall effect measure (5/9 RCTs);60</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mindfulness-based intervention:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supported by CANMAT guidelines to use as an intervention for perinatal depression of mild to moderate severity;57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>One meta-analysis of RCTs indicated that mindfulness-based interventions are efficacious in reducing depressive symptoms among perinatal individuals with mental health issues (SMD: −1.03, 95% CI: −1.48 to −0.58) and the individual results from most of these RCTs are consistent with the direction of the overall effect measure (7/9 RCTs), but some of these trials have low-quality study designs;61</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Structured exercise:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Supported by CANMAT guidelines to use for managing perinatal depression of mild to moderate severity;57</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Although this meta-analysis of RCTs demonstrated that structured exercise programs are efficacious in reducing perinatal depressive symptoms (SMD: −0.21, 95% CI: −0.31 to −0.11), the individual results from most of these RCTs are inconsistent with the direction of the overall effect measure (11/14 RCTs);82</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Antenatal Depression: SSRIs monotherapy should be considered as a first-line intervention for moderate to severe major depressive disorder**

C A consensus-based recommendation from multiple guidelines including CANMAT, COPE, and NICE;50,53,67,68 there are no existing RCTs testing SSRIs against placebo among depressed pregnant individuals.

**Postpartum Depression: SSRIs monotherapy should be considered as a first-line intervention for moderate to severe major depressive disorder**

B Guidelines including CANMAT, COPE, and NICE support SSRI monotherapy as a first-line intervention for moderate to severe postpartum depression;53,67,68 A recent Cochrane review demonstrated that SSRIs are superior to placebo in improving depressive symptoms among postnatal individuals with a depressive disorder (SMD: −0.30, 95% CI: −0.55 to −0.05) after 5 to 12 weeks of treatment, but the certainty of the evidence is low;83

**CBT can be considered as an adjunct after a clinical response to SSRI monotherapy in moderate to severe perinatal depression**

C A consensus-based recommendation from COPE guidelines; COPE recommends structured psychological interventions (e.g., CBT) as an adjunct once medications have taken effect in moderate to severe PD;57

**Abbreviations:** EPDS, Edinburgh Postnatal Depression Scale; PHQ-9, Patient Health Questionnaire-9; USPSTF, United States Preventative Service Task Force; NICE, National Institute of Health and Care Excellence; AAP, American Academy of Pediatrics; COPE, Centre of Perinatal Excellence; CDC, Centers for Disease Control and Prevention; CBT, Cognitive Behavioral Therapy; IPT, Interpersonal Psychotherapy; RR, Risk ratio; NNT, Number needed to treat; RCTs, Randomized controlled trials; SMD, Standardized mean difference; SORT, Strength of Recommendation Taxonomy; CANMAT, Canadian Network for Mood and Anxiety Treatments; SSRIs, Selective serotonin reuptake inhibitors.
the AAP recommendation of screening PPD at least at 1-, 2-, 4-, and 6-months postnatally either during well-child visits or during separate appointments.\textsuperscript{41}

The Centers for Disease Control and Prevention (CDC) recently highlighted that a large proportion of maternal deaths occur between 6 to 12 months postnatally and that mental health conditions like PD are the leading cause of perinatal maternal mortality.\textsuperscript{54} With nearly 84\% of these maternal deaths being preventable, it may also be beneficial for individuals to be screened for PPD up to 12-months postnatally.

Probable PD cases will require a diagnostic assessment for MDD defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition\textsuperscript{55} (DSM-5). Sadness and anhedonia may not be as prominent in PD compared with MDD at other times in life.\textsuperscript{56} Furthermore, elevated levels of anxiety, restlessness/ agitation, impaired concentration/decision making, and obsessional thoughts (eg, of harm coming to their infant) may be more common in PD.\textsuperscript{56–58} Significant changes in weight, appetite, sleeping patterns, and energy levels will need to be further investigated as the nature of these features may be physical complaints related to the perinatal period and not necessarily somatic symptoms of MDD.\textsuperscript{50,52} Probable cases that do not meet the diagnostic threshold for MDD can be referred to evidence-based counseling interventions including cognitive behavioral therapy (CBT) and interpersonal psychotherapy (IPT), as this is recommended by the USPSTF to help prevent PD among those with subclinical depression.\textsuperscript{59,60}

USPSTF also recommends evidence-based counseling interventions to at-risk perinatal individuals who present with or have combination of a history of depression, elevated anxiety levels, low economic resources, adolescent or single parenthood, domestic or intimate partner violence, or a history of significant negative life events.\textsuperscript{59,60} In those without risk factors for PD, psychological interventions seem to have minimal to no effect in preventing PPD.\textsuperscript{61}

Management of Perinatal Depression

Identifying and Monitoring the Severity of Perinatal Depression

Because some treatment recommendations from guidelines are based on depression severity, it is important to also be aware of DSM-5 definitions of MDD severity: 1) \textit{Mild}: Around 5 symptoms that are distressing but manageable with little impairment in social/occupational functioning; 2) \textit{Moderate}: Number and intensity of symptoms as well as functional impairment between “Mild” and “Severe”\textsuperscript{59,60} specifiers; and 3) \textit{Severe}: Substantially more than 5 symptoms that are distressing to unmanageable with markedly interference in social/occupational functioning.\textsuperscript{55} In addition to clinical judgment, the EPDS or PHQ-9 can aid PCCs in assessing improvements in PD severity. A 4-point reduction in EPDS\textsuperscript{62,63} or a 2 to 5-point reduction in PHQ-9 are suggestive of a clinically significant improvement in PD.\textsuperscript{64–66}

Mild to Moderate Perinatal Depression

For PD of mild to moderate severity, guidelines generally recommend therapist-delivered online or in-person CBT or IPT in individual or group format as a first-line intervention,\textsuperscript{50,53,67,68} as these psychotherapies have a moderate effect in treating PD.\textsuperscript{69} Although therapist-guided online psychotherapies (especially CBT) may be effective,\textsuperscript{70} their compliance may be low and dropout rates high.\textsuperscript{70}

The NICE guidelines recommend antidepressants for mild PD cases with a history of severe depression.\textsuperscript{50} However, other guidelines like those prepared by the Canadian Network for Mood and Anxiety Treatments (CANMAT; Canadian psychiatric guidelines) considers antidepressant monotherapy as a second-line intervention for mild to moderate PD\textsuperscript{67} (after therapist-delivered CBT/ IPT). However, in contexts where evidence-based psychotherapies may not be easily available, PCCs should consider selective serotonin reuptake inhibitors (SSRIs) as a first-line treatment.\textsuperscript{51} In terms of specific antidepressants, CANMAT recommends either first using sertraline, escitalopram, or citalopram.\textsuperscript{67} Sertraline or citalopram use are also supported by Danish guidelines,\textsuperscript{68} and the Agency of Health care Research and Quality from the USA supports using sertraline for PPD.\textsuperscript{71} CANMAT also specifies other antidepressants like serotonin norepinephrine reuptake inhibitors (SNRIs) can be considered as third-line options for mild to moderate PD.\textsuperscript{67} Furthermore, CANMAT recommends nortriptyline (a tricylic antidepressant [TCA]) as a third-line intervention for PPD during breastfeeding,\textsuperscript{67} given its similar efficacy to sertraline in treating PPD\textsuperscript{72} and its relatively safe lactation profile.\textsuperscript{73}

Guidelines generally do not recommend gestational paroxetine,\textsuperscript{68,71} or clomipramine\textsuperscript{67} use given their possible increased risk of congenital cardiac
Both NICE and COPE recommend CBT antidepressant for managing moderate to severe sertraline, escitalopram, or citalopram as the SSRIs, only CANMAT specifically recommends CBT for moderate to severe PPD.83 For specific SSRIs, only CANMAT specifically recommends sertraline, escitalopram, or citalopram as the first antidepressant for managing moderate to severe PPD.57 Both NICE and COPE recommend CBT for moderate to severe PPD,50,53 although COPE indicates that CBT should only be implemented after clinical response to SSRI monotherapy.53

Some individuals with moderate to severe PPD may receive treatment with brexanolone, a recently approved positive allosteric modulator of GABA type A receptors.84 One small meta-analysis of RCTs suggest brexanolone IV infusion can rapidly reduce depressive, anxious, and insomnia symptoms in PPD.86 In addition to being quite expensive,86 common adverse events include sedation, loss of consciousness, dry mouth, and hot flushes.84

Table 2: Comparison of SSRIs and SNRIs for Severe Perinatal Depression

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Effectiveness</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
</table>
| Sertraline     | Effective    | Sedation, loss of consciousness | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Escitalopram   | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Citalopram     | Effective    | Sedation, dry mouth | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Venlafaxine    | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Duloxetine     | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84

Table 2: Comparison of SSRIs and SNRIs for Severe Perinatal Depression

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Effectiveness</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
</table>
| Sertraline     | Effective    | Sedation, loss of consciousness | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Escitalopram   | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Citalopram     | Effective    | Sedation, dry mouth | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Venlafaxine    | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Duloxetine     | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84

Table 2: Comparison of SSRIs and SNRIs for Severe Perinatal Depression

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Effectiveness</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
</table>
| Sertraline     | Effective    | Sedation, loss of consciousness | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Escitalopram   | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Citalopram     | Effective    | Sedation, dry mouth | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Venlafaxine    | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Duloxetine     | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84

Table 2: Comparison of SSRIs and SNRIs for Severe Perinatal Depression

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Effectiveness</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
</table>
| Sertraline     | Effective    | Sedation, loss of consciousness | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Escitalopram   | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Citalopram     | Effective    | Sedation, dry mouth | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Venlafaxine    | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Duloxetine     | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84

Table 2: Comparison of SSRIs and SNRIs for Severe Perinatal Depression

<table>
<thead>
<tr>
<th>Antidepressant</th>
<th>Effectiveness</th>
<th>Side Effects</th>
<th>Contraindications</th>
</tr>
</thead>
</table>
| Sertraline     | Effective    | Sedation, loss of consciousness | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Escitalopram   | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Citalopram     | Effective    | Sedation, dry mouth | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Venlafaxine    | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
| Duloxetine     | Effective    | Sedation, hot flushes | History of hyper-sensitivity reactions to neuroactive steroids and end-stage renal failure.84
suggesting that early in utero exposure to venlafaxine may raise cardiac malformation risk in addition to other types of birth defects after controlling for confounds.\textsuperscript{90}

Limited data exist on the teratogenicity of tricyclic antidepressants (TCAs), but 1 meta-analysis suggests that first trimester use of most TCAs (except clomipramine) may not be associated with congenital cardiac malformations.\textsuperscript{76} Observational data suggest that early exposure to clomipramine in pregnancy may elevate the risk of cardiac malformations.\textsuperscript{77,78}

In the absence of RCT study designs testing these links, PCCs need to be aware that it is not possible to conclude that gestational antidepressant use is causally related to congenital malformation development.


\textbf{Table 2. Potential Risks of Gestational Use of Antidepressants}

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Class of antidepressants</th>
<th>Magnitude of risk</th>
<th>RCT Study Design</th>
<th>Comparator Group of pregnant individuals with clinical indication for antidepressant use</th>
<th>Statistical Adjustment for other potential confounds</th>
</tr>
</thead>
<tbody>
<tr>
<td>Congenital malformations</td>
<td>SSRIs</td>
<td>Relative risk ( \sim 1.1^{77} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Congenital cardiovascular malformations</td>
<td>SSRIs</td>
<td>Relative risk ( \sim 1.2 ) to ( 1.3^{75,76} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Spontaneous abortion</td>
<td>–</td>
<td>Relative risk ( \sim 1.5^{93} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>–</td>
<td>Relative risk ( \sim 1.2^{93} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>SSRIs</td>
<td>Relative risk ( \sim 1.4^{92} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Mean gestational age at birth</td>
<td>SSRIs</td>
<td>Mean difference: ( -0.36 ) weeks\textsuperscript{94} (3 days earlier)</td>
<td>X</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Mean 5-minute APGAR score</td>
<td>SSRIs</td>
<td>Mean difference: ( -0.32 )\textsuperscript{94} (APGAR score of 0.3 less)</td>
<td>X</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Low birthweight</td>
<td>–</td>
<td>Relative risk ( \sim 1.4^{93} )</td>
<td>X</td>
<td>✓</td>
<td>X</td>
</tr>
<tr>
<td>Preterm birth</td>
<td>SSRIs</td>
<td>Relative risk ( \sim 1.6^{17} )</td>
<td>X</td>
<td>✓</td>
<td>✓ (Race/ethnicity, parity and gestational tobacco use)</td>
</tr>
<tr>
<td>Postpartum hemorrhage</td>
<td>SSRIs</td>
<td>Relative risk ( \sim 1.2^{97} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Persistent pulmonary hypertension of newborn</td>
<td>SSRIs or SNRIs</td>
<td>Relative risk ( \sim 1.5 ) to ( 1.8^{99,100} )</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
</tbody>
</table>

\textit{Abbreviations:} SSRIs, Selective serotonin reuptake inhibitors; SNRIs, Serotonin norepinephrine reuptake inhibitors; RCTs, Randomized controlled trials; Relative risk, risk ratio and/or odds ratio.

\textit{Notes:} Risk refers to risk ratio or odds ratios from studies included in this review; Superscripts indicate citations describing the magnitude of the relative risk; A relative risk of two-fold or more (Risk \( \geq 2.0 \)) is generally accepted as being clinically significant at the level of an individual patient.\textsuperscript{36} The Symbol “X” refers to “No” and the symbol “✓” refers to “Yes”.

\textsuperscript{90} Sertraline, escitalopram, citalopram, and paroxetine seem to carry the lowest risk for spontaneous abortion, whereas fluoxetine and venlafaxine may pose a higher risk.\textsuperscript{91} In addition, gestational SSRI use may be associated with preeclampsia risk.\textsuperscript{92} Although SSRI use in pregnancy does not seem to be associated with development of gestational diabetes melitus (GDM), gestational use of either venlafaxine or amitriptyline may pose a small risk for GDM.\textsuperscript{93} Given that these results are not derived from RCTs, it is not possible to rule out that other confounding factors may affect the nature and magnitude of these links. Therefore, it is not possible to conclude that antidepressants are causally linked to these poor gestational outcomes.

\textbf{Gestational Outcomes}

Gestational antidepressant use has been linked to a small risk of spontaneous abortion\textsuperscript{93} and stillbirth\textsuperscript{93} among pregnant individuals when used in the first trimester (but not the second or third).\textsuperscript{91} Sertraline, escitalopram, citalopram, and paroxetine seem to carry the lowest risk for spontaneous abortion, whereas fluoxetine and venlafaxine may pose a higher risk.\textsuperscript{91} In addition, gestational SSRI use may be associated with preeclampsia risk.\textsuperscript{92} Although SSRI use in pregnancy does not seem to be associated with development of gestational diabetes melitus (GDM), gestational use of either venlafaxine or amitriptyline may pose a small risk for GDM.\textsuperscript{93} Given that these results are not derived from RCTs, it is not possible to rule out that other confounding factors may affect the nature and magnitude of these links. Therefore, it is not possible to conclude that antidepressants are causally linked to these poor gestational outcomes.

\textbf{Delivery and Neonatal Outcomes}

Several meta-analyses have reported that gestational antidepressant use may be linked to poor
delivery and neonatal outcomes among depressed pregnant individuals. One of these suggested gestational SSRI use may be associated with an earlier gestational age\textsuperscript{94} and lower 5-minute APGAR score.\textsuperscript{94} Gestational antidepressant use is also associated with a small increase in risk of low birth weight infants\textsuperscript{93} and preterm birth.\textsuperscript{12} Once again, lack of using RCT study designs complicate conclusions of causality among these reported associations.

Third trimester antidepressant use may slightly raise the risk of postpartum hemorrhage with risks being lower for SSRRs than SNRIs\textsuperscript{95}. In addition, third trimester antidepressant exposure may be linked to the development of poor neonatal adaptation syndrome,\textsuperscript{94,96} a combination of autonomic dysfunction, neuromuscular problems, poor feeding, and/or hypoglycemia.\textsuperscript{94,97,98} It is generally mild\textsuperscript{97} and can occur in 0 to 30\% of neonates exposed to antidepressants late in utero.\textsuperscript{97,98} It typically lasts 2 to 3 days and resolves with supportive care\textsuperscript{97} but can last longer if benzodiazepines are used concurrently.\textsuperscript{98} Paroxetine, fluoxetine, and venlafaxine may pose the highest risk.\textsuperscript{98}

Gestational serotonergic antidepressant use may modestly increase the risk of persistent pulmonary hypertension of the newborn (PPHN), with risks higher with third trimester use.\textsuperscript{100,101} However, the absolute risk of PPHN among infants exposed to serotonergic antidepressants during gestation (0.6-3.0/1000 live births)\textsuperscript{99,100} is very low and similar to infants unexposed during gestation (2.0/1000 live births).\textsuperscript{100} Furthermore, the number needed to harm is 1000 to 1615,\textsuperscript{99,100} suggesting that 1000 to 1615 pregnant individuals need to be treated with a serotonergic antidepressant to produce a single additional case of PPHN. Gestational sertraline use may have the lowest risk for PPHN followed by escitalopram, paroxetine, citalopram, and fluoxetine.\textsuperscript{100} However, 2 recent population-based studies reported no link between SSRI use either during pregnancy or specifically in the third trimester with PPHN development.\textsuperscript{98,102}

**Neurodevelopmental Outcomes**

To date, gestational antidepressant use seems to have minimal to no risk for either short- or long-term neurodevelopmental and neurobehavioral outcomes in offspring.\textsuperscript{103,104} In addition, meta-analyses examining links between gestational antidepressant use and offspring neurodevelopmental disorders (eg, autism spectrum disorder [ASD]) among pregnant individuals with mental illnesses have demonstrated no consistent statistically significant associations.\textsuperscript{105–108} Other individual observational studies adjusting for important confounding variables have also yielded no association between gestational serotonergic antidepressant use and ASD development in offspring.\textsuperscript{109}

**Offspring Outcomes during Breastfeeding**

Use of most antidepressants (including brexanolone) during lactation have reported a relative infant dose of ≤10\% among healthy infants,\textsuperscript{110,111} which is generally the threshold used to determine whether a medication is safe to use during breastfeeding.\textsuperscript{110} A recent review evaluating multiple safety parameters suggest that sertraline, paroxetine, fluvoxamine, citalopram, and escitalopram may be the safest antidepressants to use when breastfeeding.\textsuperscript{110}

One systematic review suggests the rate of adverse events among infants exposed to sertraline\textsuperscript{112} or paroxetine\textsuperscript{112} from breastmilk may be minimal (Table 3). Data on escitalopram and fluvoxamine are fewer, but their adverse event rate seems to be slightly higher.\textsuperscript{112} Fluoxetine use during lactation is associated with more adverse events in breastfed infants,\textsuperscript{112} and some suggest that this SSRI can accumulate within breastmilk given its lengthy half-life.\textsuperscript{71} Any adverse events occurring in breastfed infants often resolve spontaneously with cessation of the medication and/or breastfeeding.\textsuperscript{112} Data examining links between SSRI use during lactation and long-term developmental outcomes among breastfed infants currently suggest no associations.\textsuperscript{112}

For SNRIs, venlafaxine use during lactation has been linked to a few adverse events in breastfed infants like early neonatal weight loss and fatigue/lethargy.\textsuperscript{112,113} As for duloxetine exposure, a few breastfed infants have demonstrated dizziness, nausea, and fatigue.\textsuperscript{112,114} Among TCAs, nortriptyline may be the safest agent to use during lactation given that no cases of adverse events have been reported among 44 breastfed infants exposed to it.\textsuperscript{73} Doxepin is generally avoided during lactation as 2 infants exposed to this drug reported somnolence, difficulty breathing, poor sucking/swallowing, vomiting, and hypotonia.\textsuperscript{79}
Risks of Untreated Perinatal Depression

Maternal and Offspring Mortality

When having treatment discussions with patients, the risks of untreated PD must also be considered. Recent CDC data indicate that mental health conditions like PD are a leading cause of perinatal mortality in the USA. In other countries, severe perinatal psychiatric disorders also increase the risk of maternal mortality (Table 4), particularly perinatal suicide in the context of PD. Such findings are concerning because 7 to 10% of perinatal individuals can experience suicidal ideation independent of mental illness. In addition, PD is associated with increased risks of stillbirth and offspring postnatal mortality.

Table 3. Potential Adverse Events in Breastfed Infants Exposed to Selective Serotonin Reuptake Inhibitors During Lactation

<table>
<thead>
<tr>
<th>Individual SSRI</th>
<th>Prevalence Rate*</th>
<th>Reported Adverse Events*</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sertraline</td>
<td>2/280 cases (0.7%)</td>
<td>Sleep myoclonus, agitation, restlessness, poor feeding, insomnia</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>2/228 cases (0.9%)</td>
<td>Irritability, lethargy, poor weight gain, hypotonia</td>
</tr>
<tr>
<td>Citalopram</td>
<td>6/112 cases (5.4%)</td>
<td>Colic, decreased feeding, irritability/restlessness, sleep disturbances, hypo/hypertonia, irregular breathing</td>
</tr>
<tr>
<td>Fluoxetine</td>
<td>11/280 cases (3.9%)</td>
<td>Colic, seizures, irritability/restlessness, somnolence, lethargy, fever, unresponsiveness, watery stool, uncontrollable crying, vomiting, poor sleep</td>
</tr>
<tr>
<td>Escitalopram</td>
<td>1/37 cases (2.7%)</td>
<td>Necrotizing enterocolitis</td>
</tr>
<tr>
<td>Fluvoxamine</td>
<td>1/18 cases (5.6%)</td>
<td>Jaundice</td>
</tr>
</tbody>
</table>

Abbreviation: SSRIs, Selective serotonin reuptake inhibitors.


Table 4. Consequences of Untreated Perinatal Depression

<table>
<thead>
<tr>
<th>Outcomes</th>
<th>Magnitude of risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maternal and Offspring Mortality</td>
<td></td>
</tr>
<tr>
<td>Perinatal suicide</td>
<td>Relative risk — 2.9</td>
</tr>
<tr>
<td>Stillbirth</td>
<td>Relative risk — 1.5</td>
</tr>
<tr>
<td>Postnatal mortality of offspring</td>
<td>Relative risk — 1.9</td>
</tr>
<tr>
<td>Pregnancy and Delivery Complications</td>
<td></td>
</tr>
<tr>
<td>Gestational hypertensive disorders</td>
<td>Relative risk — 1.3</td>
</tr>
<tr>
<td>Pre-eclampsia</td>
<td>Relative risk — 1.5</td>
</tr>
<tr>
<td>Pre-term birth</td>
<td>Relative risk — 1.4 to 2.4</td>
</tr>
<tr>
<td>Low birthweight</td>
<td>Relative risk — 1.7 to 2.0</td>
</tr>
<tr>
<td>Intrauterine growth restriction</td>
<td>Relative risk — 4.1</td>
</tr>
<tr>
<td>Head growth</td>
<td>Mean difference: −0.08 mm/week</td>
</tr>
<tr>
<td>Body growth</td>
<td>Mean difference: −4.9g/week</td>
</tr>
<tr>
<td>Low 5-minute APGAR score</td>
<td>Relative risk — 1.5</td>
</tr>
<tr>
<td>Postpartum Complications</td>
<td></td>
</tr>
<tr>
<td>Infant malnutrition</td>
<td>Relative risk — 1.4</td>
</tr>
<tr>
<td>Infant physical illness</td>
<td>Relative risk — 1.7 to 2.6</td>
</tr>
<tr>
<td>Infant hospitalization</td>
<td>Relative risk — 1.4</td>
</tr>
<tr>
<td>Childhood maltreatment</td>
<td>Relative risk — 3.0</td>
</tr>
<tr>
<td>Exclusively breastfeeding</td>
<td>Relative risk — 0.5 to 0.8</td>
</tr>
<tr>
<td>Partner depression</td>
<td>Relative risk — 1.2 to 1.7</td>
</tr>
<tr>
<td>Offspring depression</td>
<td>Relative risk — 1.7</td>
</tr>
</tbody>
</table>

Abbreviation: APGAR score, Apgar stands for “Appearance, Pulse, Grimace, Activity, and Respiration.” In the test, these five things are used to check a baby’s health. Relative risk, risk ratio and/or odds ratio.

Note: Superscripts indicate citations describing the magnitude of the relative risk. A relative risk of two-fold or more (Risk ≥ 2.0) is generally accepted as being clinically significant at the level of an individual patient.
Figure 1. Suggested algorithm for detection and management of perinatal depression within primary care.

Screen perinatal individual to identify probable case of perinatal depression
EPDS ≥ 11 or PHQ-9 ≥ 10 indicates probable case of perinatal MDD

Not a probable case of perinatal depression
Screen again either with EPDS or PHQ-9 during:
Pregnancy – at least during 1st trimester and 3rd trimester
Postpartum – at least 1-, 2-, 4-, and 6-months postnatally
*Consider screening up to 12-months postnatally to reduce postpartum maternal mortality

Probable case of perinatal depression
Diagnostic evaluation for DSM-5 defined MDD

Does not meet DSM-5 criteria for perinatal MDD
(Case of subclinical perinatal depression)
Refer to programs offering counseling interventions to prevent perinatal MDD onset

DSM-5 Mild Perinatal MDD
Around 5 symptoms that are distressing but manageable with little impairment in social/occupational functioning

DSM-5 Moderate Perinatal MDD
Number and intensity of symptoms as well as functional impairment between “mild” and “severe” specifiers

DSM-5 Severe Perinatal MDD
Substantially more than 5 symptoms that are distressing to unmanageable with markedly interference in social/occupational functioning

Interventions for DSM-5 mild to moderate perinatal MDD
1st line: Therapist-delivered in-person or online CBT or IPT in individual or group format
2nd line: SSRI monotherapy (preferably sertraline, escitalopram, or citalopram)
3rd line: Other antidepressant monotherapy (e.g., fluvoxamine or nortriptyline)
Adjuncts – consider (1) social/peer-support; (2) mindfulness-based interventions; or (3) structured exercise programs (e.g., walking) of moderate intensity (≥150 mins/week)

Interventions for DSM-5 moderate to severe perinatal MDD
1st line: SSRI monotherapy (preferably sertraline, escitalopram, or citalopram)
2nd line: Other antidepressant monotherapy (e.g., fluvoxamine or nortriptyline)
Adjunct – consider CBT

Abbreviations: EPDS, Edinburgh postnatal depression scale; PHQ-9, Patient health questionnaire-9; MDD, Major depressive disorder; DSM-5, Diagnostic statistical manual of mental disorders, fifth edition; CBT, Cognitive behavioral therapy; IPT, Interpersonal psychotherapy; SSRI, Selective serotonin reuptake inhibitor.
Pregnancy and Delivery Complications

AD is linked to an increased risk of gestational hypertensive disorders\(^5\) including preeclampsia\(^6\) and higher rates of preterm birth\(^{12-16}\) and low birth weight neonates.\(^{14,15}\) Moreover, AD is associated with intrauterine growth restriction,\(^{16}\) smaller head growth,\(^{17}\) decreased body growth,\(^{17}\) and lower 5-minute APGAR scores.\(^{12}\)

Postpartum Complications

PPD is associated with more offspring physical illness,\(^7,8\) hospitalization,\(^7\) and maltreatment\(^{116}\) as well as a decreased likelihood of exclusive breastfeeding.\(^{19,20}\) In addition, PPD may be linked with poorer maternal-infant attachment,\(^{18}\) less optimal parenting practices,\(^{17}\) and may elevate the risk of depression in partners\(^{26,27}\) and offspring.\(^{24}\)

Offspring Developmental Problems

Offspring of individuals with PD report more socio-emotional,\(^{21,22}\) cognitive,\(^{22,23,25}\) behavioral,\(^{22}\) and language\(^{22}\) related developmental problems. In particular, PPD can increase the risk of emotional, behavioral and peer-related problems in offspring.\(^{22}\) Furthermore, PPD is linked to poorer general\(^{25}\) and performance IQ,\(^{22}\) memory,\(^{22}\) executive functioning,\(^{23}\) and academic achievement\(^{22}\) among offspring.

Conclusion

Screening with EPDS or PHQ-9 followed by a diagnostic evaluation for MDD in probable cases can enhance detection of PD. At-risk individuals and mild to moderate PD cases should be referred to therapist-delivered CBT or IPT if possible. SSRIs should be used for moderate to severe PD, with sertraline, escitalopram, or citalopram being preferred first. Generally, using paroxetine or clomipramine in pregnancy and fluoxetine or doxepin during lactation is not preferred. Antidepressant use in pregnancy and lactation has been linked to negative outcomes, but lack of RCTs testing these links limits the ability to conclude whether perinatal antidepressant use is causally related to any of the reported risks discussed in this review. Lastly, a discussion of the consequences of untreated PD can aid PCCs in their conversations with PD cases about the benefits and harms of using antidepressants. Use of these recommendations can help further enhance the high-quality care PCCs provide to those with PD, accelerating recovery with benefits for them and their families.

To see this article online, please go to: http://jabfm.org/content/36/6/1071.full.

References


86. Faden J, Citrome L. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used? Ther Adv Psychopharmacol 2020;10:2045125320968658.


